Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Substance Withdrawal Syndrome 1Prostatic Neoplasms 1Overweight 1Obesity 1Melanoma 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 9Letrozole 5Anastrozole 5Radiotherapy 3Radiation 3Neoadjuvant Therapy 3afimoxifene 2Trastuzumab 2Surgical Procedures, Operative 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Mastectomy, Segmental 2Lapatinib 2Gene Expression Profiling 2trastuzumab biosimilar HLX02 1telapristone acetate 1sargramostim 1polyphenon E 1pasireotide 1palbociclib 1oxybutynin 1liposomal doxorubicin 1exemestane 1Zoledronic Acid 1UAB 30 1Tea 1Sugars 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Intraductal, Noninfiltrating × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡